Evidence map›Paper›PMID 40373109›Full record

ArticlePloS one2025

A combined risk model shows viability for personalized breast cancer risk assessment in the Indonesian population: A case/control study.

Bijak Rabbani, Sabrina Gabriel Tanu, Kevin Nathanael Ramanto, Jessica Audrienna, Eric Aria Fernandez, Fatma Aldila, Mar Gonzalez-Porta, Margareta Deidre Valeska, Jessline Haruman, Lorina Handayani Ulag and 14 more

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Bijak RabbaniPT Nalagenetik Riset Indonesia, Jakarta, Indonesia.
Sabrina Gabriel TanuPT Nalagenetik Riset Indonesia, Jakarta, Indonesia.
Kevin Nathanael RamantoPT Nalagenetik Riset Indonesia, Jakarta, Indonesia.
Jessica AudriennaPT Nalagenetik Riset Indonesia, Jakarta, Indonesia.
Eric Aria FernandezPT Nalagenetik Riset Indonesia, Jakarta, Indonesia.
Fatma AldilaPT Nalagenetik Riset Indonesia, Jakarta, Indonesia.ORCID https://orcid.org/0000-0002-1927-1703
Mar Gonzalez-PortaNalagenetics Pte Ltd, Lower Delta Road, #04-05/06/07/08, Singapore.ORCID https://orcid.org/0000-0002-1661-7254
Margareta Deidre ValeskaPT Nalagenetik Riset Indonesia, Jakarta, Indonesia.
Jessline HarumanPT Nalagenetik Riset Indonesia, Jakarta, Indonesia.
Lorina Handayani UlagPT Nalagenetik Riset Indonesia, Jakarta, Indonesia.
Yusuf MaulanaPT Nalagenetik Riset Indonesia, Jakarta, Indonesia.
Kathleen Irena JunusminPT Nalagenetik Riset Indonesia, Jakarta, Indonesia.
Margareta AmeliaPT Nalagenetik Riset Indonesia, Jakarta, Indonesia.
Gabriella GabriellaPT Nalagenetik Riset Indonesia, Jakarta, Indonesia.
Feilicia SoetyonoPT Nalagenetik Riset Indonesia, Jakarta, Indonesia.
Aulian FajarrahmanPT Nalagenetik Riset Indonesia, Jakarta, Indonesia.
Salma Syahfani Maudina HasanPT Nalagenetik Riset Indonesia, Jakarta, Indonesia.
Faustina Audrey AgathaSJH Initiatives, MRCCC Siloam Hospitals Semanggi, Jakarta, Indonesia.
Marco WijayaSJH Initiatives, MRCCC Siloam Hospitals Semanggi, Jakarta, Indonesia.
Stevany Tiurma Br SorminSJH Initiatives, MRCCC Siloam Hospitals Semanggi, Jakarta, Indonesia.
Levana SaniPT Nalagenetik Riset Indonesia, Jakarta, Indonesia.
Astrid IrwantoNalagenetics Pte Ltd, Lower Delta Road, #04-05/06/07/08, Singapore.
Samuel J HaryonoSJH Initiatives, MRCCC Siloam Hospitals Semanggi, Jakarta, Indonesia.
Soegianto AliBiomedicine Department, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer remains a significant concern worldwide, with a rising incidence in Indonesia. This study aims to evaluate the applicability of risk-based screening approaches in the Indonesian demographic through a case-control study involving 305 women. We developed a personalized breast cancer risk assessment workflow that integrates multiple risk factors, including clinical (Gail) and polygenic (Mavaddat) risk predictions, into a consolidated risk category. By evaluating the area under the receiver operating characteristic curve (AUC) of each single-factor risk model, we demonstrated that they retained their predictive accuracy in the Indonesian context (AUC for clinical risk: 0.67 [0.61,0.74]; AUC for genetic risk: 0.67 [0.61,0.73]). Notably, our combined risk approach enhanced the AUC to 0.70 [0.64,0.76], highlighting the advantages of a multifaceted model. Our findings demonstrate for the first time the applicability of the Mavaddat and Gail models to Indonesian populations, and show that within this demographic, combined risk models provide a superior predictive framework compared to single-factor approaches.

Indexed as

Breast NeoplasmsAdultAgedCase-Control StudiesFemaleHumansIndonesiaMiddle AgedPrecision MedicineRisk AssessmentRisk FactorsROC Curve

Identifiers

PMID40373109
PMCPMC12080871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.